CINXE.COM

<!DOCTYPE html> <html lang="en" dir="ltr"> <head>  <script async src="https://www.googletagmanager.com/gtag/js?id=G-P63WKM1TM1"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-P63WKM1TM1'); </script>  <script type="text/javascript" > (function(m,e,t,r,i,k,a){m[i]=m[i]||function(){(m[i].a=m[i].a||[]).push(arguments)}; m[i].l=1*new Date(); for (var j = 0; j < document.scripts.length; j++) {if (document.scripts[j].src === r) { return; }} k=e.createElement(t),a=e.getElementsByTagName(t)[0],k.async=1,k.src=r,a.parentNode.insertBefore(k,a)}) (window, document, "script", "https://mc.yandex.ru/metrika/tag.js", "ym"); ym(55165297, "init", { clickmap:false, trackLinks:true, accurateTrackBounce:true, webvisor:false }); </script> <noscript><div><img src="https://mc.yandex.ru/watch/55165297" style="position:absolute; left:-9999px;" alt="" /></div></noscript>    <title>Search results for: patient-derived xenograft</title> <meta name="description" content="Search results for: patient-derived xenograft"> <meta name="keywords" content="patient-derived xenograft"> <meta name="viewport" content="width=device-width, initial-scale=1, minimum-scale=1, maximum-scale=1, user-scalable=no"> <meta charset="utf-8"> <link href="https://cdn.waset.org/favicon.ico" type="image/x-icon" rel="shortcut icon"> <link href="https://cdn.waset.org/static/plugins/bootstrap-4.2.1/css/bootstrap.min.css" rel="stylesheet"> <link href="https://cdn.waset.org/static/plugins/fontawesome/css/all.min.css" rel="stylesheet"> <link href="https://cdn.waset.org/static/css/site.css?v=150220211555" rel="stylesheet"> </head> <body> <header> <div class="container"> <nav class="navbar navbar-expand-lg navbar-light"> <a class="navbar-brand" href="https://waset.org"> <img src="https://cdn.waset.org/static/images/wasetc.png" alt="Open Science Research Excellence" title="Open Science Research Excellence" /> </a> <button class="d-block d-lg-none navbar-toggler ml-auto" type="button" data-toggle="collapse" data-target="#navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"> <span class="navbar-toggler-icon"></span> </button> <div class="w-100"> <div class="d-none d-lg-flex flex-row-reverse"> <form method="get" action="https://waset.org/search" class="form-inline my-2 my-lg-0"> <input class="form-control mr-sm-2" type="search" placeholder="Search Conferences" value="patient-derived xenograft" name="q" aria-label="Search"> <button class="btn btn-light my-2 my-sm-0" type="submit"><i class="fas fa-search"></i></button> </form> </div> <div class="collapse navbar-collapse mt-1" id="navbarMenu"> <ul class="navbar-nav ml-auto align-items-center" id="mainNavMenu"> <li class="nav-item"> <a class="nav-link" href="https://waset.org/conferences" title="Conferences in 2024/2025/2026">Conferences</a> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/disciplines" title="Disciplines">Disciplines</a> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/committees" rel="nofollow">Committees</a> </li> <li class="nav-item dropdown"> <a class="nav-link dropdown-toggle" href="#" id="navbarDropdownPublications" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> Publications </a> <div class="dropdown-menu" aria-labelledby="navbarDropdownPublications"> <a class="dropdown-item" href="https://publications.waset.org/abstracts">Abstracts</a> <a class="dropdown-item" href="https://publications.waset.org">Periodicals</a> <a class="dropdown-item" href="https://publications.waset.org/archive">Archive</a> </div> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/page/support" title="Support">Support</a> </li> </ul> </div> </div> </nav> </div> </header> <main> <div class="container mt-4"> <div class="row"> <div class="col-md-9 mx-auto"> <form method="get" action="https://publications.waset.org/abstracts/search"> <div id="custom-search-input"> <div class="input-group"> <i class="fas fa-search"></i> <input type="text" class="search-query" name="q" placeholder="Author, Title, Abstract, Keywords" value="patient-derived xenograft"> <input type="submit" class="btn_search" value="Search"> </div> </div> </form> </div> </div> <div class="row mt-3"> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Commenced</strong> in January 2007</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Frequency:</strong> Monthly</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Edition:</strong> International</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Paper Count:</strong> 21</div> </div> </div> </div> <h1 class="mt-3 mb-3 text-center" style="font-size:1.6rem;">Search results for: patient-derived xenograft</h1> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">21</span> Immunologically Non-Treated Vascular Xenografts in Long-Term Survival Animals </h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=W.%20G.%20Kim">W. G. Kim</a>, <a href="https://publications.waset.org/abstracts/search?q=J.%20M.%20Chang"> J. M. Chang</a>, <a href="https://publications.waset.org/abstracts/search?q=W.%20S.%20Kim"> W. S. Kim</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Immunologically non-treated and acellularized porcine xenografts were implanted as an arterial graft in goats and comparatively analyzed for the explanted grafts with gross observation, as well as light microscopy and immunohistochemistry, following the predetermined periods. For immunologically non-treated xenografts, bilateral porcine carotid arteries were harvested, and after short-term freezing at -70°C, were implanted into goats. The preparation of acellularized xenograft vessels has been performed with Nacl-SDS solution and stored at the freezer until use. The goats were randomly assigned for three periods of observation (3, 6, and 12 months after implantation), four animals were observed at each of these times. Periodic ultrasonographic examinations were performed during observation period. Following the predetermined periods, the explanted grafts were analyzed. Among 12 animals, one goat died prematurely, and a total of 22 grafts were evaluated. Gross observations revealed non-thrombotic patent smooth lumens. Microscopic examinations of the explanted grafts showed satisfactory cellular reconstruction up to the 12-month observation period. The proportions of CD3 positive T lymphocytes among inflammatory cells infiltrations were very low. In conclusion, these findings, as a whole, suggest that porcine vessel xenografts can be clinically acceptably implanted in the goats as a form of small-diameter vascular graft, regardless of the acellularized xenograft or immunologically non-treated xenograft. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=xenograft" title="xenograft">xenograft</a>, <a href="https://publications.waset.org/abstracts/search?q=arterial%20graft" title=" arterial graft"> arterial graft</a>, <a href="https://publications.waset.org/abstracts/search?q=long-term%20survival%20animals" title=" long-term survival animals"> long-term survival animals</a>, <a href="https://publications.waset.org/abstracts/search?q=immunology" title=" immunology"> immunology</a> </p> <a href="https://publications.waset.org/abstracts/9211/immunologically-non-treated-vascular-xenografts-in-long-term-survival-animals" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/9211.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">349</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">20</span> Effect of Engineered Low Glycemic Foods on Cancer Progression and Healthy State</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=C.%20Panebianco">C. Panebianco</a>, <a href="https://publications.waset.org/abstracts/search?q=K.%20Adamberg"> K. Adamberg</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20Adamberg"> S. Adamberg</a>, <a href="https://publications.waset.org/abstracts/search?q=C.%20Saracino"> C. Saracino</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20Jaagura"> M. Jaagura</a>, <a href="https://publications.waset.org/abstracts/search?q=K.%20Kolk"> K. Kolk</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20Di%20Chio"> A. Di Chio</a>, <a href="https://publications.waset.org/abstracts/search?q=P.%20Graziano"> P. Graziano</a>, <a href="https://publications.waset.org/abstracts/search?q=R.%20Vilu"> R. Vilu</a>, <a href="https://publications.waset.org/abstracts/search?q=V.%20Pazienza"> V. Pazienza</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background/Aims: Despite recent advances in treatment options, a modest impact on the outcome of the pancreatic cancer (PC) is observed so far. Short-term fasting cycles have the potential to improve the efficacy of chemotherapy against PC. However, diseased people may refuse to follow the fasting regimen and fasting may worsen the weight loss often occurring in cancer patients. Therefore, alternative approaches are needed. The aim of this study was to assess the effect of Engineered Low glycemic food ELGIF mimicking diet on growth of cancer cell lines in vitro and in an in vivo pancreatic cancer mouse xenograft model. Materials and Methods: BxPC-3, MiaPaca-2 and Panc-1 cells were cultured in control and ELGIF mimicking diet culturing condition to evaluate the tumor growth and proliferation pathways. Pancreatic cancer xenograft mice were subjected to ELGIF to assess the tumor volume and weight as compared to mice fed with control diet. Results: Pancreatic cancer cells cultured in ELGIF mimicking medium showed decreased levels of proliferation as compared to those cultured in the standard medium. Consistently, xenograft pancreatic cancer mice subjected to ELGIF diet displayed a significant decrease in tumor growth. Conclusion: A positive effect of ELGIF diet on proliferation in vitro is associated with the decrease of tumor progression in the in vivo PC xenograft mouse model. These results suggest that engineered dietary interventions could be supportive as synergistic approach to enhance the efficacy of existing cancer treatments in pancreatic cancer patients. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=functional%20food" title="functional food">functional food</a>, <a href="https://publications.waset.org/abstracts/search?q=microbiota" title=" microbiota"> microbiota</a>, <a href="https://publications.waset.org/abstracts/search?q=mouse%20model" title=" mouse model"> mouse model</a>, <a href="https://publications.waset.org/abstracts/search?q=pancreatic%20cancer" title=" pancreatic cancer"> pancreatic cancer</a> </p> <a href="https://publications.waset.org/abstracts/51926/effect-of-engineered-low-glycemic-foods-on-cancer-progression-and-healthy-state" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/51926.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">290</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">19</span> Characterization of Herberine Hydrochloride Nanoparticles</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Bao-Fang%20Wen">Bao-Fang Wen</a>, <a href="https://publications.waset.org/abstracts/search?q=Meng-Na%20Dai"> Meng-Na Dai</a>, <a href="https://publications.waset.org/abstracts/search?q=Gao-Pei%20Zhu"> Gao-Pei Zhu</a>, <a href="https://publications.waset.org/abstracts/search?q=Chen-Xi%20Zhang"> Chen-Xi Zhang</a>, <a href="https://publications.waset.org/abstracts/search?q=Jing%20Sun"> Jing Sun</a>, <a href="https://publications.waset.org/abstracts/search?q=Xun-Bao%20Yin"> Xun-Bao Yin</a>, <a href="https://publications.waset.org/abstracts/search?q=Yu-Han%20Zhao"> Yu-Han Zhao</a>, <a href="https://publications.waset.org/abstracts/search?q=Hong-Wei%20Sun"> Hong-Wei Sun</a>, <a href="https://publications.waset.org/abstracts/search?q=Wei-Fen%20Zhang"> Wei-Fen Zhang</a> </p> <p class="card-text"><strong>Abstract:</strong></p> A drug-loaded nanoparticles containing berberine hydrochloride (BH/FA-CTS-NPs) was prepared. The physicochemical characterizations of BH/FA-CTS-NPs and the inhibitory effect on the HeLa cells were investigated. Folic acid-conjugated chitosan (FA-CTS) was prepared by amino reaction of folic acid active ester and chitosan molecules; BH/FA-CTS-NPs were prepared using ionic cross-linking technique with BH as a model drug. The morphology and particle size were determined by Transmission Electron Microscope (TEM). The average diameters and polydispersity index (PDI) were evaluated by Dynamic Light Scattering (DLS). The interaction between various components and the nanocomplex were characterized by Fourier Transform Infrared Spectroscopy (FT-IR). The entrapment efficiency (EE), drug-loading (DL) and in vitro release were studied by UV spectrophotometer. The effect of cell anti-migratory and anti-invasive actions of BH/FA-CTS-NPs were investigated using MTT assays, wound healing assays, Annexin-V-FITC single staining assays, and flow cytometry, respectively. HeLa nude mice subcutaneously transplanted tumor model was established and treated with different drugs to observe the effect of BH/FA-CTS-NPs in vivo on HeLa bearing tumor. The BH/FA-CTS-NPs prepared in this experiment have a regular shape, uniform particle size, and no aggregation phenomenon. The results of DLS showed that mean particle size, PDI and Zeta potential of BH/FA-CTS NPs were (249.2 ± 3.6) nm, 0.129 ± 0.09, 33.6 ± 2.09, respectively, and the average diameter and PDI were stable in 90 days. The results of FT-IR demonstrated that the characteristic peaks of FA-CTS and BH/FA-CTS-NPs confirmed that FA-CTS cross-linked successfully and BH was encapsulated in NPs. The EE and DL amount were (79.3 ± 3.12) % and (7.24 ± 1.41) %, respectively. The results of in vitro release study indicated that the cumulative release of BH/FA-CTS NPs was (89.48±2.81) % in phosphate-buffered saline (PBS, pH 7.4) within 48h; these results by MTT assays and wund healing assays indicated that BH/FA-CTS NPs not only inhibited the proliferation of HeLa cells in a concentration and time-dependent manner but can induce apoptosis as well. The subcutaneous xenograft tumor formation rate of human cervical cancer cell line HeLa in nude mice was 98% after inoculation for 2 weeks. Compared with BH group and BH/CTS-NPs group, the xenograft tumor growth of BH/FA-CTS-NPs group was obviously slower; the result indicated that BH/FA-CTS-NPs could significantly inhibit the growth of HeLa xenograft tumor. BH/FA-CTS NPs with the sustained release effect could be prepared successfully by the ionic crosslinking method. Considering these properties, block proliferation and impairing the migration of the HeLa cell line, BH/FA-CTS NPs could be an important compound for consideration in the treatment of cervical cancer. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=folic-acid" title="folic-acid">folic-acid</a>, <a href="https://publications.waset.org/abstracts/search?q=chitosan" title=" chitosan"> chitosan</a>, <a href="https://publications.waset.org/abstracts/search?q=berberine%20hydrochloride" title=" berberine hydrochloride"> berberine hydrochloride</a>, <a href="https://publications.waset.org/abstracts/search?q=nanoparticles" title=" nanoparticles"> nanoparticles</a>, <a href="https://publications.waset.org/abstracts/search?q=cervical%20cancer" title=" cervical cancer"> cervical cancer</a> </p> <a href="https://publications.waset.org/abstracts/110474/characterization-of-herberine-hydrochloride-nanoparticles" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/110474.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">122</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">18</span> Atypical Retinoid ST1926 Nanoparticle Formulation Development and Therapeutic Potential in Colorectal Cancer</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Sara%20Assi">Sara Assi</a>, <a href="https://publications.waset.org/abstracts/search?q=Berthe%20Hayar"> Berthe Hayar</a>, <a href="https://publications.waset.org/abstracts/search?q=Claudio%20Pisano"> Claudio Pisano</a>, <a href="https://publications.waset.org/abstracts/search?q=Nadine%20Darwiche"> Nadine Darwiche</a>, <a href="https://publications.waset.org/abstracts/search?q=Walid%20Saad"> Walid Saad</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Nanomedicine, the application of nanotechnology to medicine, is an emerging discipline that has gained significant attention in recent years. Current breakthroughs in nanomedicine have paved the way to develop effective drug delivery systems that can be used to target cancer. The use of nanotechnology provides effective drug delivery, enhanced stability, bioavailability, and permeability, thereby minimizing drug dosage and toxicity. As such, the use of nanoparticle (NP) formulations in drug delivery has been applied in various cancer models and have shown to improve the ability of drugs to reach specific targeted sites in a controlled manner. Cancer is one of the major causes of death worldwide; in particular, colorectal cancer (CRC) is the third most common type of cancer diagnosed amongst men and women and the second leading cause of cancer related deaths, highlighting the need for novel therapies. Retinoids, consisting of natural and synthetic derivatives, are a class of chemical compounds that have shown promise in preclinical and clinical cancer settings. However, retinoids are limited by their toxicity and resistance to treatment. To overcome this resistance, various synthetic retinoids have been developed, including the adamantyl retinoid ST1926, which is a potent anti-cancer agent. However, due to its limited bioavailability, the development of ST1926 has been restricted in phase I clinical trials. We have previously investigated the preclinical efficacy of ST1926 in CRC models. ST1926 displayed potent inhibitory and apoptotic effects in CRC cell lines by inducing early DNA damage and apoptosis. ST1926 significantly reduced the tumor doubling time and tumor burden in a xenograft CRC model. Therefore, we developed ST1926-NPs and assessed their efficacy in CRC models. ST1926-NPs were produced using Flash NanoPrecipitation with the amphiphilic diblock copolymer polystyrene-b-ethylene oxide and cholesterol as a co-stabilizer. ST1926 was formulated into NPs with a drug to polymer mass ratio of 1:2, providing a stable formulation for one week. The contin ST1926-NP diameter was 100 nm, with a polydispersity index of 0.245. Using the MTT cell viability assay, ST1926-NP exhibited potent anti-growth activities as naked ST1926 in HCT116 cells, at pharmacologically achievable concentrations. Future studies will be performed to study the anti-tumor activities and mechanism of action of ST1926-NPs in a xenograft mouse model and to detect the compound and its glucuroconjugated form in the plasma of mice. Ultimately, our studies will support the use of ST1926-NP formulations in enhancing the stability and bioavailability of ST1926 in CRC. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=nanoparticles" title="nanoparticles">nanoparticles</a>, <a href="https://publications.waset.org/abstracts/search?q=drug%20delivery" title=" drug delivery"> drug delivery</a>, <a href="https://publications.waset.org/abstracts/search?q=colorectal%20cancer" title=" colorectal cancer"> colorectal cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=retinoids" title=" retinoids"> retinoids</a> </p> <a href="https://publications.waset.org/abstracts/163716/atypical-retinoid-st1926-nanoparticle-formulation-development-and-therapeutic-potential-in-colorectal-cancer" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/163716.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">100</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">17</span> An Activatable Theranostic for Targeted Cancer Therapy and Imaging</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Sankarprasad%20Bhuniya">Sankarprasad Bhuniya</a>, <a href="https://publications.waset.org/abstracts/search?q=Sukhendu%20Maiti"> Sukhendu Maiti</a>, <a href="https://publications.waset.org/abstracts/search?q=Eun-Joong%20Kim"> Eun-Joong Kim</a>, <a href="https://publications.waset.org/abstracts/search?q=Hyunseung%20Lee"> Hyunseung Lee</a>, <a href="https://publications.waset.org/abstracts/search?q=Jonathan%20L.%20Sessler"> Jonathan L. Sessler</a>, <a href="https://publications.waset.org/abstracts/search?q=Kwan%20Soo%20Hong"> Kwan Soo Hong</a>, <a href="https://publications.waset.org/abstracts/search?q=Jong%20Seung%20Kim"> Jong Seung Kim</a> </p> <p class="card-text"><strong>Abstract:</strong></p> A new theranostic strategy is described. It is based on the use of an “all in one” prodrug, namely the biotinylated piperazine-rhodol conjugate 4a. This conjugate, which incorporates the anticancer drug SN-38, undergoes self-immolative cleavage when exposed to biological thiols. This leads to the tumor-targeted release of the active SN-38 payload along with fluorophore 1a. This release is made selective as the result of the biotin functionality. Fluorophore 1a is 32-fold more fluorescent than prodrug 4a. It permits the delivery and release of the SN-38 payload to be monitored easily in vitro and in vivo, as inferred from cell studies and ex vivo analyses of mice xenografts derived HeLa cells, respectively. Prodrug 4a also displays anticancer activity in the HeLa cell murine xenograft tumor model. On the basis of these findings we suggest that the present strategy, which combines within a single agent the key functions of targeting, release, imaging, and treatment, may have a role to play in cancer diagnosis and therapy. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=theranostic" title="theranostic">theranostic</a>, <a href="https://publications.waset.org/abstracts/search?q=prodrug" title=" prodrug"> prodrug</a>, <a href="https://publications.waset.org/abstracts/search?q=cancer%20therapy" title=" cancer therapy"> cancer therapy</a>, <a href="https://publications.waset.org/abstracts/search?q=fluorescence" title=" fluorescence"> fluorescence</a> </p> <a href="https://publications.waset.org/abstracts/16859/an-activatable-theranostic-for-targeted-cancer-therapy-and-imaging" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/16859.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">537</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">16</span> Immunoliposomes Conjugated with CD133 Antibody for Targeting Melanoma Cancer Stem Cells</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Chuan%20Yin">Chuan Yin</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Cancer stem cells (CSCs) represent a subpopulation of cancer cells that possess the characteristics associated with normal stem cells. CD133 is a phenotype of melanoma CSCs responsible for melanoma metastasis and drug resistance. Although adriamycin (ADR) is commonly used drug in melanoma therapy, but it is ineffective in the treatment of melanoma CSCs. In this study, we constructed CD133 antibody conjugated ADR immunoliposomes (ADR-Lip-CD133) to target CD133+ melanoma CSCs. The results showed that the immunoliposomes possessed a small particle size (~150 nm), high drug encapsulation efficiency (~90%). After 72 hr treatment on the WM266-4 melanoma tumorspheres, the IC50 values of the drug formulated in ADR-Lip-CD133, ADR-Lip (ADR liposomes) and ADR are found to be 24.42, 57.13 and 59.98 ng/ml respectively, suggesting that ADR-Lip-CD133 was more effective than ADR-Lip and ADR. Significantly, ADR-Lip-CD133 could almost completely abolish the tumorigenic ability of WM266-4 tumorspheres in vivo, and showed the best therapeutic effect in WM266-4 melanoma xenograft mice. It is noteworthy that ADR-Lip-CD133 could selectively kill CD133+ melanoma CSCs of WM266-4 cells both in vitro and in vivo. ADR-Lip-CD133 represent a potential approach in targeting and killing CD133+ melanoma CSCs. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=cancer%20stem%20cells" title="cancer stem cells">cancer stem cells</a>, <a href="https://publications.waset.org/abstracts/search?q=melanoma" title=" melanoma"> melanoma</a>, <a href="https://publications.waset.org/abstracts/search?q=immunoliposomes" title=" immunoliposomes"> immunoliposomes</a>, <a href="https://publications.waset.org/abstracts/search?q=CD133" title=" CD133"> CD133</a> </p> <a href="https://publications.waset.org/abstracts/32389/immunoliposomes-conjugated-with-cd133-antibody-for-targeting-melanoma-cancer-stem-cells" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/32389.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">382</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">15</span> The Predictive Significance of Metastasis Associated in Colon Cancer-1 (MACC1) in Primary Breast Cancer</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Jasminka%20Mujic">Jasminka Mujic</a>, <a href="https://publications.waset.org/abstracts/search?q=Karin%20Milde-Langosch"> Karin Milde-Langosch</a>, <a href="https://publications.waset.org/abstracts/search?q=Volkmar%20Mueller"> Volkmar Mueller</a>, <a href="https://publications.waset.org/abstracts/search?q=Mirza%20Suljagic"> Mirza Suljagic</a>, <a href="https://publications.waset.org/abstracts/search?q=Tea%20Becirevic"> Tea Becirevic</a>, <a href="https://publications.waset.org/abstracts/search?q=Jozo%20Coric"> Jozo Coric</a>, <a href="https://publications.waset.org/abstracts/search?q=Daria%20Ler"> Daria Ler</a> </p> <p class="card-text"><strong>Abstract:</strong></p> MACC1 (metastasis associated in colon cancer-1) is a prognostic biomarker for tumor progression, metastasis, and survival of a variety of solid cancers. MACC1 also causes tumor growth in xenograft models and acts as a master regulator of the HGF/MET signaling pathway. In breast cancer, the expression of MACC1 determined by immunohistochemistry was significantly associated with positive lymph node status and advanced clinical stage. The aim of the present study was to further investigate the prognostic or predictive value of MACC1 expression in breast cancer using western blot analysis and immunohistochemistry. The results of our study have shown that high MACC1 expression in breast cancer is associated with shorter disease-free survival, especially in node-negative tumors. The MACC1 might be a suitable biomarker to select patients with a higher probability of recurrence which might benefit from adjuvant chemotherapy. Our results support a biologic role and potentially open the perspective for the use of MACC1 as predictive biomarker for treatment decision in breast cancer patients. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=breast%20cancer" title="breast cancer">breast cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=biomarker" title=" biomarker"> biomarker</a>, <a href="https://publications.waset.org/abstracts/search?q=HGF%2FMET" title=" HGF/MET"> HGF/MET</a>, <a href="https://publications.waset.org/abstracts/search?q=MACC1" title=" MACC1"> MACC1</a> </p> <a href="https://publications.waset.org/abstracts/86514/the-predictive-significance-of-metastasis-associated-in-colon-cancer-1-macc1-in-primary-breast-cancer" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/86514.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">233</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">14</span> Xenografts: Successful Penetrating Keratoplasty Between Two Species</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Francisco%20Alvarado">Francisco Alvarado</a>, <a href="https://publications.waset.org/abstracts/search?q=Luz%20Ram%C3%ADrez"> Luz Ramírez</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Corneal diseases are one of the main causes of visual impairment and affect almost 4 million, and this study assesses the effects of deep anterior lamellar keratoplasty (DALK) with porcine corneal stroma and postoperative topical treatment with tacrolimus in patients with infectious keratitis. No patient was observed with clinical graft rejection. Among the cases: 2 were positive to fungal culture, 2 with Aspergillus and the other 8 cases were confirmed by bacteriological culture. Corneal diseases are one of the main causes of visual impairment and affect almost 4 million. This study assesses the effects of deep anterior lamellar keratoplasty (DALK) with porcine corneal stroma and postoperative topical treatment with tacrolimus in patients with infectious keratitis. Receiver bed diameters ranged from 7.00 to 9.00 mm. No incidents of Descemet's membrane perforation were observed during surgery. During the follow-up period, no corneal graft splitting, IOP increase, or intolerance to tacrolimus were observed. Deep anterior lamellar keratoplasty seems to be the best option to avoid xenograft rejection, and it could help new surgical techniques in humans. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=ophthalmology" title="ophthalmology">ophthalmology</a>, <a href="https://publications.waset.org/abstracts/search?q=cornea" title=" cornea"> cornea</a>, <a href="https://publications.waset.org/abstracts/search?q=corneal%20transplant" title=" corneal transplant"> corneal transplant</a>, <a href="https://publications.waset.org/abstracts/search?q=xenografts" title=" xenografts"> xenografts</a>, <a href="https://publications.waset.org/abstracts/search?q=surgical%20innovations" title=" surgical innovations"> surgical innovations</a> </p> <a href="https://publications.waset.org/abstracts/151388/xenografts-successful-penetrating-keratoplasty-between-two-species" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/151388.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">83</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">13</span> Hollowfiber Poly Lactid Co-Glycolic Acid (PLGA)-Collagen Coated by Chitosan as a Candidate of Small Diameter Vascular Graft</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Dita%20Mayasari">Dita Mayasari</a>, <a href="https://publications.waset.org/abstracts/search?q=Zahrina%20Mardina"> Zahrina Mardina</a>, <a href="https://publications.waset.org/abstracts/search?q=Riki%20Siswanto"> Riki Siswanto</a>, <a href="https://publications.waset.org/abstracts/search?q=Agresta%20%20Ifada"> Agresta Ifada</a>, <a href="https://publications.waset.org/abstracts/search?q=Ova%20Oktavina"> Ova Oktavina</a>, <a href="https://publications.waset.org/abstracts/search?q=Prihartini%20Widiyanti"> Prihartini Widiyanti</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Heart failure is a serious major health problem with high number of mortality per year. Bypass is one of the solutions that has often been taken. Natural vascular graft (xenograft) as the substitute in bypass is inconvenient due to ethic problems and the risk of infection transmission caused by the usage of another species transgenic vascular. Nowadays, synthetic materials have been fabricated from polymers. The aim of this research is to make a synthetic vascular graft with great physical strength, high biocompatibility, and good affordability. The method of this research was mixing PLGA and collagen by magnetic stirrer. This composite were shaped by spinneret with water as coagulant. Then it was coated by chitosan with 3 variations of weight (1 gram, 2 grams, and 3 grams) to increase hemo and cytocompatibility, proliferation, and cell attachment in order for the vascular graft candidates to be more biocompatible. Mechanical strength for each variation was 5,306 MPa (chitosan 1 gram), 3,433 MPa (chitosan 2 grams) and 3,745 MPa (chitosan 3 grams). All the tensile values were higher than human vascular tensile strength. Toxicity test showed that the living cells in all variations were more than 60% in number, thus the vascular graft is not toxic. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=chitosan" title="chitosan">chitosan</a>, <a href="https://publications.waset.org/abstracts/search?q=collagen" title=" collagen"> collagen</a>, <a href="https://publications.waset.org/abstracts/search?q=PLGA" title=" PLGA"> PLGA</a>, <a href="https://publications.waset.org/abstracts/search?q=spinneret" title=" spinneret"> spinneret</a> </p> <a href="https://publications.waset.org/abstracts/3156/hollowfiber-poly-lactid-co-glycolic-acid-plga-collagen-coated-by-chitosan-as-a-candidate-of-small-diameter-vascular-graft" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/3156.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">398</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">12</span> Autophagy Regulates Human Hepatocellular Carcinoma Tumorigenesis through Selective Degradation of Cyclin D1</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Shan-Ying%20Wu">Shan-Ying Wu</a>, <a href="https://publications.waset.org/abstracts/search?q=Sheng-Hui%20Lan"> Sheng-Hui Lan</a>, <a href="https://publications.waset.org/abstracts/search?q=Xi-Zhang%20Lin"> Xi-Zhang Lin</a>, <a href="https://publications.waset.org/abstracts/search?q=Ih-Jen%20Su"> Ih-Jen Su</a>, <a href="https://publications.waset.org/abstracts/search?q=Ting-Fen%20Tsai"> Ting-Fen Tsai</a>, <a href="https://publications.waset.org/abstracts/search?q=Chia-Jui%20Yen"> Chia-Jui Yen</a>, <a href="https://publications.waset.org/abstracts/search?q=Tsung-Hsueh%20Lu"> Tsung-Hsueh Lu</a>, <a href="https://publications.waset.org/abstracts/search?q=Fu-Wen%20Liang"> Fu-Wen Liang</a>, <a href="https://publications.waset.org/abstracts/search?q=Huey-Jen%20Su"> Huey-Jen Su</a>, <a href="https://publications.waset.org/abstracts/search?q=Chun-Li%20Su"> Chun-Li Su</a>, <a href="https://publications.waset.org/abstracts/search?q=Hsiao-Sheng%20Liu"> Hsiao-Sheng Liu</a> </p> <p class="card-text"><strong>Abstract:</strong></p> In hepatocelluar carcinoma (HCC), dysregulated expression of cyclin D1 and impaired autophagy has been reported separately. However, the relationship between them has not been explored. In this study, we demonstrated that autophagy was inversely correlated with cyclin D1 expression in 147 paired HCC patient specimens. HCC specimen with highly expression of cyclin D1 shows correlation with poor overall survival rate. Furthermore, induction of autophagy by amiodarone (antiarrhythmic drug) in Hep 3B cells, cyclin D1 was recruited into autophagosomes demonstrated by immune-gold labeling of cyclin D1 after extraction of autophagosomes. We further demonstrated that autophagy suppresses Hep 3B cell proliferation, and further analysis revealed that cell cycle was arrested at G1 phase. The interaction between LC3 (maker of autophagy) and cyclin D1 was increased after autophagy induction. In addition, ubiquitinated-cyclin D1 was also increased after autophagy induction, which is selectively degraded by autophagosome through binding with SQSTM1/p62 (an adaptor protein). In vivo study showed that amiodarone induced autophagy suppresses liver tumor formation in xenograft mouse and orthotopic rat model through decreasing cyclin D1 expression and inhibition of cell proliferation. Altogether, we reveal a novel mechanism that ubiquitinated cyclin D1 degraded by autophagic pathway by p62 and amiodarone is a promising drug for targeting cyclin D1 in liver cancer therapy. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=autophagy" title="autophagy">autophagy</a>, <a href="https://publications.waset.org/abstracts/search?q=cyclin%20D1" title=" cyclin D1"> cyclin D1</a>, <a href="https://publications.waset.org/abstracts/search?q=hepatocellular%20carcinoma" title=" hepatocellular carcinoma"> hepatocellular carcinoma</a>, <a href="https://publications.waset.org/abstracts/search?q=amiodarone" title=" amiodarone"> amiodarone</a> </p> <a href="https://publications.waset.org/abstracts/56136/autophagy-regulates-human-hepatocellular-carcinoma-tumorigenesis-through-selective-degradation-of-cyclin-d1" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/56136.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">295</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">11</span> Sequential Release of Dual Drugs Using Thermo-Sensitive Hydrogel for Tumor Vascular Inhibition and to Enhance the Efficacy of Chemotherapy</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Haile%20F.%20Darge">Haile F. Darge</a>, <a href="https://publications.waset.org/abstracts/search?q=Hsieh%20C.%20Tsai"> Hsieh C. Tsai</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The tumor microenvironment affects the therapeutic outcomes of cancer disease. In a malignant tumor, overexpression of vascular endothelial growth factor (VEGF) provokes the production of pathologic vascular networks. This results in a hostile tumor environment that hinders anti-cancer drug activities and profoundly fuels tumor progression. In this study, we develop a strategy of sequential sustain release of the anti-angiogenic drug: Bevacizumab(BVZ), and anti-cancer drug: Doxorubicin(DOX) which had a synergistic effect on cancer treatment. Poly (D, L-Lactide)- Poly (ethylene glycol) –Poly (D, L-Lactide) (PDLLA-PEG-PDLLA) thermo-sensitive hydrogel was used as a vehicle for local delivery of drugs in a single platform. The in vitro release profiles of the drugs were investigated and confirmed a relatively rapid release of BVZ (73.56 ± 1.39%) followed by Dox (61.21 ± 0.62%) for a prolonged period. The cytotoxicity test revealed that the copolymer exhibited negligible cytotoxicity up to 2.5 mg ml-1 concentration on HaCaT and HeLa cells. The in vivo study on Hela xenograft nude mice verified that hydrogel co-loaded with BVZ and DOX displayed the highest tumor suppression efficacy for up to 36 days with pronounce anti-angiogenic effect of BVZ and with no noticeable damage on vital organs. Therefore, localized co-delivery of anti-angiogenic drug and anti-cancer drugs by the hydrogel system may be a promising approach for enhanced chemotherapeutic efficacy in cancer treatment. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=anti-angiogenesis" title="anti-angiogenesis">anti-angiogenesis</a>, <a href="https://publications.waset.org/abstracts/search?q=chemotherapy" title=" chemotherapy"> chemotherapy</a>, <a href="https://publications.waset.org/abstracts/search?q=controlled%20release" title=" controlled release"> controlled release</a>, <a href="https://publications.waset.org/abstracts/search?q=thermo-sensitive%20hydrogel" title=" thermo-sensitive hydrogel"> thermo-sensitive hydrogel</a> </p> <a href="https://publications.waset.org/abstracts/118621/sequential-release-of-dual-drugs-using-thermo-sensitive-hydrogel-for-tumor-vascular-inhibition-and-to-enhance-the-efficacy-of-chemotherapy" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/118621.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">134</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">10</span> Double-Spear 1-H2-1 Oncolytic-Immunotherapy for Refractory and Relapsing High-Risk Human Neuroblastoma and Glioma</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Lian%20Zeng">Lian Zeng</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Double-Spear 1-H2-1 (DS1-H2-1) is an oncolytic virus and an innovative biological drug candidate. The chemical composition of the drug product is a live attenuated West Nile virus (WNV) containing the human T cell costimulator (CD86) gene. After intratumoral injection, the virus can rapidly self-replicate in the injected site and lyse/kill the tumor by repeated infection among tumor cells. We also established xenograft tumor models in mice to evaluate the drug candidate's efficacy on those tumors. The results from preclinical studies on transplanted tumors in immunodeficient mice showed that DS1-H2-1 had significant oncolytic effects on human-origin cancers: it completely (100%) shrieked human glioma; limited human neuroblastoma growth reached as high as 95% growth inhibition rate (%TGITW). The safety data of preclinical animal experiments confirmed that DS1-H2-1 is safe as a biological drug for clinical use. In the preclinical drug efficacy experiment, virus-drug administration with different doses did not show abnormal signs and disease symptoms in more than 300 tested mice, and no side effects or death occurred through various administration routes. Intravenous administration did not cause acute infectious disease or other side effects. However, the replication capacity of the virus in tumor tissue via intravenous administration is only 1% of that of direct intratumoral administration. The direct intratumoral administration of DS1-H2-1 had a higher rate of viral replication. Therefore, choosing direct intratumoral injection can ensure both efficacy and safety. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=oncolytic%20virus" title="oncolytic virus">oncolytic virus</a>, <a href="https://publications.waset.org/abstracts/search?q=WNV-CD86" title=" WNV-CD86"> WNV-CD86</a>, <a href="https://publications.waset.org/abstracts/search?q=immunotherapy%20drugs" title=" immunotherapy drugs"> immunotherapy drugs</a>, <a href="https://publications.waset.org/abstracts/search?q=glioma" title=" glioma"> glioma</a>, <a href="https://publications.waset.org/abstracts/search?q=neuroblastoma" title=" neuroblastoma"> neuroblastoma</a> </p> <a href="https://publications.waset.org/abstracts/163981/double-spear-1-h2-1-oncolytic-immunotherapy-for-refractory-and-relapsing-high-risk-human-neuroblastoma-and-glioma" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/163981.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">130</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">9</span> Towards a Biologically Relevant Tumor-on-a-Chip: Multiplex Microfluidic Platform to Study Breast Cancer Drug Response </h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Soroosh%20Torabi">Soroosh Torabi</a>, <a href="https://publications.waset.org/abstracts/search?q=Brad%20Berron"> Brad Berron</a>, <a href="https://publications.waset.org/abstracts/search?q=Ren%20Xu"> Ren Xu</a>, <a href="https://publications.waset.org/abstracts/search?q=Christine%20Trinkle"> Christine Trinkle</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Microfluidics integrated with 3D cell culture is a powerful technology to mimic cellular environment, and can be used to study cell activities such as proliferation, migration and response to drugs. This technology has gained more attention in cancer studies over the past years, and many organ-on-a-chip systems have been developed to study cancer cell behaviors in an ex-vivo tumor microenvironment. However, there are still some barriers to adoption which include low throughput, complexity in 3D cell culture integration and limitations on non-optical analysis of cells. In this study, a user-friendly microfluidic multi-well plate was developed to mimic the in vivo tumor microenvironment. The microfluidic platform feeds multiple 3D cell culture sites at the same time which enhances the throughput of the system. The platform uses hydrophobic Cassie-Baxter surfaces created by microchannels to enable convenient loading of hydrogel/cell suspensions into the device, while providing barrier free placement of the hydrogel and cells adjacent to the fluidic path. The microchannels support convective flow and diffusion of nutrients to the cells and a removable lid is used to enable further chemical and physiological analysis on the cells. Different breast cancer cell lines were cultured in the device and then monitored to characterize nutrient delivery to the cells as well as cell invasion and proliferation. In addition, the drug response of breast cancer cell lines cultured in the device was compared to the response in xenograft models to the same drugs to analyze relevance of this platform for use in future drug-response studies. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=microfluidics" title="microfluidics">microfluidics</a>, <a href="https://publications.waset.org/abstracts/search?q=multi-well%203d%20cell%20culture" title=" multi-well 3d cell culture"> multi-well 3d cell culture</a>, <a href="https://publications.waset.org/abstracts/search?q=tumor%20microenvironment" title=" tumor microenvironment"> tumor microenvironment</a>, <a href="https://publications.waset.org/abstracts/search?q=tumor-on-a-chip" title=" tumor-on-a-chip"> tumor-on-a-chip</a> </p> <a href="https://publications.waset.org/abstracts/91076/towards-a-biologically-relevant-tumor-on-a-chip-multiplex-microfluidic-platform-to-study-breast-cancer-drug-response" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/91076.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">264</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">8</span> Lymphomas as Estrogen-Regulated Cancers</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=M.%20S.%20Hasni">M. S. Hasni</a>, <a href="https://publications.waset.org/abstracts/search?q=J.%20Guan"> J. Guan</a>, <a href="https://publications.waset.org/abstracts/search?q=K.%20Yakimchuk"> K. Yakimchuk</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20Berglund"> M. Berglund</a>, <a href="https://publications.waset.org/abstracts/search?q=B.%20Sander"> B. Sander</a>, <a href="https://publications.waset.org/abstracts/search?q=G.%20Enblad"> G. Enblad</a>, <a href="https://publications.waset.org/abstracts/search?q=R.%20M.%20Amini"> R. M. Amini</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20Okret"> S. Okret</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Lymphomas are generally not considered as endocrine-related cancers. However, most lymphoid malignancies show gender differences in incidence and show prognosis with males being more affected. Furthermore, some epidemiological data indicate a protective role of estrogens against Non-Hodgkin lymphomas. Recent studies have demonstrated estrogen receptor β (ERβ) to be the major ER expressed in normal and malignant cells of lymphoid origin. We have analyzed the effects of estradiol and selective ERα and ERβ agonists on lymphoma growth in culture and in vivo. Treating lymphoma cells with estradiol or ERα selective agonist had minor or no effect on cell growth while selective ERβ agonist treatment showed an antiproliferative effect. When grafting mice with murine T lymphoma cells, male mice developed larger tumors compared to female mice, a difference that was abolished following ovariectomy, demonstrating estrogen-dependent growth in vivo. When subcutaneously grafting lymphoma cells to mice, so far growth of all tested human B lymphoma tumors (Raji and Ramos Burkitt lymphoma, SU.DHL4 (GC) and U2932 (ABC) DLBCL, Granta-519, Maver1 and Z138 MCL cells), were reduced following treatment with ERβ selective agonist (ref. 2 and unpublished). Moreover, the number and size of liver foci of disseminating Raji cells was reduced. We have identified target genes and mechanism that could explain the above effects of ERβ agonists. This included effects on angio and lymphangiogenesis. Now we have further analyzed effects of ERβ agonists on Ibrutinib-sensitive and -insensitive MCL cells in xenograft experiments as well as ERβ expression in primary lymphoma material (DLBCL). Preliminary statistical analysis has been done correlating ERβ expression to other biomarkers and clinical data. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=lymphomas" title="lymphomas">lymphomas</a>, <a href="https://publications.waset.org/abstracts/search?q=estrogen%20receptors" title=" estrogen receptors"> estrogen receptors</a>, <a href="https://publications.waset.org/abstracts/search?q=cancer" title=" cancer"> cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=liver%20foci" title=" liver foci"> liver foci</a> </p> <a href="https://publications.waset.org/abstracts/17116/lymphomas-as-estrogen-regulated-cancers" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/17116.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">411</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">7</span> Hydrophobically Modified Glycol Chitosan Nanoparticles as a Carrier for Etoposide</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Akhtar%20Aman">Akhtar Aman</a>, <a href="https://publications.waset.org/abstracts/search?q=Abida%20Raza"> Abida Raza</a>, <a href="https://publications.waset.org/abstracts/search?q=Shumaila%20Bashir"> Shumaila Bashir</a>, <a href="https://publications.waset.org/abstracts/search?q=Javaid%20Irfan"> Javaid Irfan</a>, <a href="https://publications.waset.org/abstracts/search?q=Andreas%20G.%20Sch%C3%A4tzlein"> Andreas G. Schätzlein</a>, <a href="https://publications.waset.org/abstracts/search?q=Ijeoma%20F%20Uchegbeu"> Ijeoma F Uchegbeu</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Development of efficient delivery system for hydrophobic drugs remains a major concern in chemotherapy. The objective of the current study was to develop polymeric drug-delivery system for etoposide from amphiphilic derivatives of glycol chitosan, capable to improve the pharmacokinetics and to reduce the adverse effects of etoposide due to various organic solvents used in commercial formulations for solubilisation of etoposide. As a promising carrier, amphiphilic derivatives of glycol chitosan were synthesized by chemical grafting of palmitic acid N-hydroxy succinimide and quaternisation to glycol chitosan backbone. To this end a 7.9 kDa glycol chitosan was modified by palmitoylation and quaternisation into 13 kDa. Nano sized micelles prepared from this amphiphilic polymer had the capability to encapsulate up to 3 mg/ml etoposide. The pharmacokinetic results indicated that GCPQ based etoposide formulation transformed the biodistribution pattern. AUC 0.5-24 hr showed statistically significant difference in ETP-GCPQ vs. commercial preparation in liver (25 vs 70, p<0.001), spleen (27 vs. 36, P<0.05), lungs (42 vs. 136, p<0.001), kidneys (25 vs. 30, p<0.05) and brain (19 vs. 9,p<0.001). Using the hydrophobic fluorescent dye Nile red, we showed that micelles efficiently delivered their payload to MCF7 and A2780 cancer cells in-vitro and to A431 xenograft tumor in-vivo, suggesting these systems could deliver hydrophobic anti- cancer drugs such as etoposide to tumors. The pharmacokinetic results indicated that the GCPQ micelles transformed the biodistribution pattern and increased etoposide concentration in the brain significantly compared to free drug after intravenous administration. GCPQ based formulations not only reduced side effects associated with current available formulations but also increased their transport through the biological barriers, thus making it a good delivery system. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=glycol%20chitosan" title="glycol chitosan">glycol chitosan</a>, <a href="https://publications.waset.org/abstracts/search?q=Nile%20red" title=" Nile red"> Nile red</a>, <a href="https://publications.waset.org/abstracts/search?q=micelles" title=" micelles"> micelles</a>, <a href="https://publications.waset.org/abstracts/search?q=etoposide" title=" etoposide"> etoposide</a>, <a href="https://publications.waset.org/abstracts/search?q=A431%20xenografts" title=" A431 xenografts"> A431 xenografts</a> </p> <a href="https://publications.waset.org/abstracts/15339/hydrophobically-modified-glycol-chitosan-nanoparticles-as-a-carrier-for-etoposide" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/15339.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">310</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">6</span> Noncovalent Antibody-Nanomaterial Conjugates: A Simple Approach to Produce Targeted Nanomedicines</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Nicholas%20Fletcher">Nicholas Fletcher</a>, <a href="https://publications.waset.org/abstracts/search?q=Zachary%20Houston"> Zachary Houston</a>, <a href="https://publications.waset.org/abstracts/search?q=Yongmei%20Zhao"> Yongmei Zhao</a>, <a href="https://publications.waset.org/abstracts/search?q=Christopher%20Howard"> Christopher Howard</a>, <a href="https://publications.waset.org/abstracts/search?q=Kristofer%20Thurecht"> Kristofer Thurecht</a> </p> <p class="card-text"><strong>Abstract:</strong></p> One promising approach to enhance nanomedicine therapeutic efficacy is to include a targeting agent, such as an antibody, to increase accumulation at the tumor site. However, the application of such targeted nanomedicines remains limited, in part due to difficulties involved with biomolecule conjugation to synthetic nanomaterials. One approach recently developed to overcome this has been to engineer bispecific antibodies (BsAbs) with dual specificity, whereby one portion binds to methoxy polyethyleneglycol (mPEG) epitopes present on synthetic nanomedicines, while the other binds to molecular disease markers of interest. In this way, noncovalent complexes of nanomedicine core, comprising a hyperbranched polymer (HBP) of primarily mPEG, decorated with targeting ligands are able to be produced by simple mixing. Further work in this area has now demonstrated such complexes targeting the breast cancer marker epidermal growth factor receptor (EGFR) to show enhanced binding to tumor cells both in vitro and in vivo. Indeed the enhanced accumulation at the tumor site resulted in improved therapeutic outcomes compared to untargeted nanomedicines and free chemotherapeutics. The current work on these BsAb-HBP conjugates focuses on further probing antibody-nanomaterial interactions and demonstrating broad applicability to a range of cancer types. Herein are reported BsAb-HBP materials targeted towards prostate-specific membrane antigen (PSMA) and study of their behavior in vivo using ⁸⁹Zr positron emission tomography (PET) in a dual-tumor prostate cancer xenograft model. In this model mice bearing both PSMA+ and PSMA- tumors allow for PET imaging to discriminate between nonspecific and targeted uptake in tumors, and better quantify the increased accumulation following BsAb conjugation. Also examined is the potential for formation of these targeted complexes in situ following injection of individual components? The aim of this approach being to avoid undesirable clearance of proteinaceous complexes upon injection limiting available therapeutic. Ultimately these results demonstrate BsAb functionalized nanomaterials as a powerful and versatile approach for producing targeted nanomedicines for a variety of cancers. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=bioengineering" title="bioengineering">bioengineering</a>, <a href="https://publications.waset.org/abstracts/search?q=cancer" title=" cancer"> cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=nanomedicine" title=" nanomedicine"> nanomedicine</a>, <a href="https://publications.waset.org/abstracts/search?q=polymer%20chemistry" title=" polymer chemistry"> polymer chemistry</a> </p> <a href="https://publications.waset.org/abstracts/89152/noncovalent-antibody-nanomaterial-conjugates-a-simple-approach-to-produce-targeted-nanomedicines" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/89152.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">141</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5</span> MicroRNA Drivers of Resistance to Androgen Deprivation Therapy in Prostate Cancer</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Philippa%20Saunders">Philippa Saunders</a>, <a href="https://publications.waset.org/abstracts/search?q=Claire%20Fletcher"> Claire Fletcher</a> </p> <p class="card-text"><strong>Abstract:</strong></p> INTRODUCTION: Prostate cancer is the most prevalent malignancy affecting Western males. It is initially an androgen-dependent disease: androgens bind to the androgen receptor and drive the expression of genes that promote proliferation and evasion of apoptosis. Despite reduced androgen dependence in advanced prostate cancer, androgen receptor signaling remains a key driver of growth. Androgen deprivation therapy (ADT) is, therefore, a first-line treatment approach and works well initially, but resistance inevitably develops. Abiraterone and Enzalutamide are drugs widely used in ADT and are androgen synthesis and androgen receptor signaling inhibitors, respectively. The shortage of other treatment options means acquired resistance to these drugs is a major clinical problem. MicroRNAs (miRs) are important mediators of post-transcriptional gene regulation and show altered expression in cancer. Several have been linked to the development of resistance to ADT. Manipulation of such miRs may be a pathway to breakthrough treatments for advanced prostate cancer. This study aimed to validate ADT resistance-implicated miRs and their clinically relevant targets. MATERIAL AND METHOD: Small RNA-sequencing of Abiraterone- and Enzalutamide-resistant C42 prostate cancer cells identified subsets of miRs dysregulated as compared to parental cells. Real-Time Quantitative Reverse Transcription PCR (qRT-PCR) was used to validate altered expression of candidate ADT resistance-implicated miRs 195-5p, 497-5p and 29a-5p in ADT-resistant and -responsive prostate cancer cell lines, patient-derived xenografts (PDXs) and primary prostate cancer explants. RESULTS AND DISCUSSION: This study suggests a possible role for miR-497-5p in the development of ADT resistance in prostate cancer. MiR-497-5p expression was increased in ADT-resistant versus ADT-responsive prostate cancer cells. Importantly, miR-497-5p expression was also increased in Enzalutamide-treated, castrated (ADT-mimicking) PDXs versus intact PDXs. MiR-195-5p was also elevated in ADT-resistant versus -responsive prostate cancer cells, while there was a drop in miR-29a-5p expression. Candidate clinically relevant targets of miR-497-5p in prostate cancer were identified by mining AGO-PAR-CLIP-seq data sets and may include AVL9 and FZD6. CONCLUSION: In summary, this study identified microRNAs that are implicated in prostate cancer resistance to androgen deprivation therapy and could represent novel therapeutic targets for advanced disease. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=microRNA" title="microRNA">microRNA</a>, <a href="https://publications.waset.org/abstracts/search?q=androgen%20deprivation%20therapy" title=" androgen deprivation therapy"> androgen deprivation therapy</a>, <a href="https://publications.waset.org/abstracts/search?q=Enzalutamide" title=" Enzalutamide"> Enzalutamide</a>, <a href="https://publications.waset.org/abstracts/search?q=abiraterone" title=" abiraterone"> abiraterone</a>, <a href="https://publications.waset.org/abstracts/search?q=patient-derived%20xenograft" title=" patient-derived xenograft"> patient-derived xenograft</a> </p> <a href="https://publications.waset.org/abstracts/159310/microrna-drivers-of-resistance-to-androgen-deprivation-therapy-in-prostate-cancer" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/159310.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">143</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">4</span> Barrier Membrane Influence Histology of Guided Bone Regenerations: A Systematic Review and Meta-Analysis</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Laura%20Canagueral-Pellice">Laura Canagueral-Pellice</a>, <a href="https://publications.waset.org/abstracts/search?q=Antonio%20Munar-Frau"> Antonio Munar-Frau</a>, <a href="https://publications.waset.org/abstracts/search?q=Adaia%20Valls-Ontanon"> Adaia Valls-Ontanon</a>, <a href="https://publications.waset.org/abstracts/search?q=Joao%20Carames"> Joao Carames</a>, <a href="https://publications.waset.org/abstracts/search?q=Federico%20Hernandez-Alfaro"> Federico Hernandez-Alfaro</a>, <a href="https://publications.waset.org/abstracts/search?q=Jordi%20Caballe-Serrano"> Jordi Caballe-Serrano</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Objective: Guided bone regeneration (GBR) aims to replace the missing bone with a new structure to achieve long-term stability of rehabilitations. The aim of the present systematic review and meta-analysis is to determine the effect of barrier membranes on histological outcomes after GBR procedures. Moreover, the effect of the grafting material and tissue gain were analyzed. Materials & methods: Two independent reviewers performed an electronic search in Pubmed and Scopus, identifying all eligible publications up to March 2020. Only randomized controlled trials (RCTs) assessing a histological analysis of augmented areas were included. Results: A total of 6 publications were included for the present systematic review. A total of 110 biopsied sites were analysed; 10 corresponded to vertical bone augmentation procedures, whereas 100 analysed horizontal regeneration procedures. A mean tissue gain of 3 ± 1.48mm was obtained for horizontal defects. Histological assessment of new bone formation, residual particle and sub-epithelial connective tissue (SCT) was reported. The four main barrier membranes used were natural collagen membranes, e-PTFE, polylactic resorbable membranes and acellular dermal matrix membranes (AMDG). The analysis demonstrated that resorbable membranes result in higher values of new bone formation and lower values of residual particles and SCT. Xenograft resulted in lower new bone formation compared to allograft; however, no statistically significant differences were observed regarding residual particle and SCT. Overall, regeneration procedures adding autogenous bone, plasma derivate or growth factors achieved in general greater new bone formation and tissue gain. Conclusions: There is limited evidence favoring the effect of a certain type of barrier membrane in GBR. Data needs to be evaluated carefully; however, resorbable membranes are correlated with greater new bone formation values, especially when combined with allograft materials and/or the addition of autogenous bone, platelet reach plasma (PRP) or growth factors in the regeneration area. More studies assessing the histological outcomes of different GBR protocols and procedures testing different biomaterials are needed to maximize the clinical and histological outcomes in bone regeneration science. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=barrier%20membrane" title="barrier membrane">barrier membrane</a>, <a href="https://publications.waset.org/abstracts/search?q=graft%20material" title=" graft material"> graft material</a>, <a href="https://publications.waset.org/abstracts/search?q=guided%20bone%20regeneration" title=" guided bone regeneration"> guided bone regeneration</a>, <a href="https://publications.waset.org/abstracts/search?q=implant%20surgery" title=" implant surgery"> implant surgery</a>, <a href="https://publications.waset.org/abstracts/search?q=histology" title=" histology"> histology</a> </p> <a href="https://publications.waset.org/abstracts/140170/barrier-membrane-influence-histology-of-guided-bone-regenerations-a-systematic-review-and-meta-analysis" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/140170.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">152</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">3</span> Targeted Delivery of Docetaxel Drug Using Cetuximab Conjugated Vitamin E TPGS Micelles Increases the Anti-Tumor Efficacy and Inhibit Migration of MDA-MB-231 Triple Negative Breast Cancer</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=V.%20K.%20Rajaletchumy">V. K. Rajaletchumy</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20L.%20Chia"> S. L. Chia</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20I.%20Setyawati"> M. I. Setyawati</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20S.%20Muthu"> M. S. Muthu</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20S.%20Feng"> S. S. Feng</a>, <a href="https://publications.waset.org/abstracts/search?q=D.%20T.%20Leong"> D. T. Leong</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Triple negative breast cancers (TNBC) can be classified as one of the most aggressive with a high rate of local recurrences and systematic metastases. TNBCs are insensitive to existing hormonal therapy or targeted therapies such as the use of monoclonal antibodies, due to the lack of oestrogen receptor (ER) and progesterone receptor (PR) and the absence of overexpression of human epidermal growth factor receptor 2 (HER2) compared with other types of breast cancers. The absence of targeted therapies for selective delivery of therapeutic agents into tumours, led to the search for druggable targets in TNBC. In this study, we developed a targeted micellar system of cetuximab-conjugated micelles of D-α-tocopheryl polyethylene glycol succinate (vitamin E TPGS) for targeted delivery of docetaxel as a model anticancer drug for the treatment of TNBCs. We examined the efficacy of our micellar system in xenograft models of triple negative breast cancers and explored the effect of the micelles on post-treatment tumours in order to elucidate the mechanism underlying the nanomedicine treatment in oncology. The targeting micelles were found preferentially accumulated in tumours immediately after the administration of the micelles compare to normal tissue. The fluorescence signal gradually increased up to 12 h at the tumour site and sustained for up to 24 h, reflecting the increases in targeted micelles (TPFC) micelles in MDA-MB-231/Luc cells. In comparison, for the non-targeting micelles (TPF), the fluorescence signal was evenly distributed all over the body of the mice. Only a slight increase in fluorescence at the chest area was observed after 24 h post-injection, reflecting the moderate uptake of micelles by the tumour. The successful delivery of docetaxel into tumour by the targeted micelles (TPDC) exhibited a greater degree of tumour growth inhibition than Taxotere® after 15 days of treatment. The ex vivo study has demonstrated that tumours treated with targeting micelles exhibit enhanced cell cycle arrest and attenuated proliferation compared with the control and with those treated non-targeting micelles. Furthermore, the ex vivo investigation revealed that both the targeting and non-targeting micellar formulations shows significant inhibition of cell migration with migration indices reduced by 0.098- and 0.28-fold, respectively, relative to the control. Overall, both the in vivo and ex vivo data increased the confidence that our micellar formulations effectively targeted and inhibited EGF-overexpressing MDA-MB-231 tumours. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=biodegradable%20polymers" title="biodegradable polymers">biodegradable polymers</a>, <a href="https://publications.waset.org/abstracts/search?q=cancer%20nanotechnology" title=" cancer nanotechnology"> cancer nanotechnology</a>, <a href="https://publications.waset.org/abstracts/search?q=drug%20targeting" title=" drug targeting"> drug targeting</a>, <a href="https://publications.waset.org/abstracts/search?q=molecular%20biomaterials" title=" molecular biomaterials"> molecular biomaterials</a>, <a href="https://publications.waset.org/abstracts/search?q=nanomedicine" title=" nanomedicine"> nanomedicine</a> </p> <a href="https://publications.waset.org/abstracts/50350/targeted-delivery-of-docetaxel-drug-using-cetuximab-conjugated-vitamin-e-tpgs-micelles-increases-the-anti-tumor-efficacy-and-inhibit-migration-of-mda-mb-231-triple-negative-breast-cancer" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/50350.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">281</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2</span> Fresh Amnion Membrane Grafting for the Regeneration of Skin in Full Thickness Burn in Newborn - Case Report</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Priyanka%20Yadav">Priyanka Yadav</a>, <a href="https://publications.waset.org/abstracts/search?q=Umesh%20Bnasal"> Umesh Bnasal</a>, <a href="https://publications.waset.org/abstracts/search?q=Yashvinder%20Kumar"> Yashvinder Kumar</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The placenta is an important structure that provides oxygen and nutrients to the growing fetus in utero. It is usually thrown away after birth, but it has a therapeutic role in the regeneration of tissue. It is covered by the amniotic membrane, which can be easily separated into the amnion layer and the chorion layer—the amnion layer act as a biofilm for the healing of burn wound and non-healing ulcers. The freshly collected membrane has stem cells, cytokines, growth factors, and anti-inflammatory properties, which act as a biofilm for the healing of wounds. It functions as a barrier and prevents heat and water loss and also protects from bacterial contamination, thus supporting the healing process. The application of Amnion membranes has been successfully used for wound and reconstructive purposes for decades. It is a very cheap and easy process and has shown superior results to allograft and xenograft. However, there are very few case reports of amnion membrane grafting in newborns; we intend to highlight its therapeutic importance in burn injuries in newborns. We present a case of 9 days old male neonate who presented to the neonatal unit of Maulana Azad Medical College with a complaint of fluid-filled blisters and burns wound on the body for six days. He was born outside the hospital at 38 weeks of gestation to a 24-year-old primigravida mother by vaginal delivery. The presentation was cephalic and the amniotic fluid was clear. His birth weight was 2800 gm and APGAR scores were 7 and 8 at 1 and 5 minutes, respectively. His anthropometry was appropriate for gestational age. He developed respiratory distress after birth requiring oxygen support by nasal prongs for three days. On the day of life three, he developed blisters on his body, starting from than face then over the back and perineal region. At a presentation on the day of life nine, he had blisters and necrotic wound on the right side of the face, back, right shoulder and genitalia, affecting 60% of body surface area with full-thickness loss of skin. He was started on intravenous antibiotics and fluid therapy. Pus culture grew Pseudomonas aeuroginosa, for which culture-specific antibiotics were started. Plastic surgery reference was taken and regular wound dressing was done with antiseptics. He had a storming course during the hospital stay. On the day of life 35 when the baby was hemodynamically stable, amnion membrane grafting was done on the wound site; for the grafting, fresh amnion membrane was removed under sterile conditions from the placenta obtained by caesarean section. It was then transported to the plastic surgery unit in half an hour in a sterile fluid where the graft was applied over the infant’s wound. The amnion membrane grafting was done twice in two weeks for covering the whole wound area. After successful uptake of amnion membrane, skin from the thigh region was autografted over the whole wound area by Meek technique in a single setting. The uptake of autograft was excellent and most of the areas were healed. In some areas, there was patchy regeneration of skin so dressing was continued. The infant was discharged after three months of hospital stay and was later followed up in the plastic surgery unit of the hospital. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=amnion%20membrane%20grafting" title="amnion membrane grafting">amnion membrane grafting</a>, <a href="https://publications.waset.org/abstracts/search?q=autograft" title=" autograft"> autograft</a>, <a href="https://publications.waset.org/abstracts/search?q=meek%20technique" title=" meek technique"> meek technique</a>, <a href="https://publications.waset.org/abstracts/search?q=newborn" title=" newborn"> newborn</a>, <a href="https://publications.waset.org/abstracts/search?q=regeneration%20of%20skin" title=" regeneration of skin"> regeneration of skin</a> </p> <a href="https://publications.waset.org/abstracts/141973/fresh-amnion-membrane-grafting-for-the-regeneration-of-skin-in-full-thickness-burn-in-newborn-case-report" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/141973.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">161</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1</span> Magnesium Nanoparticles for Photothermal Therapy</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=E.%20Locatelli">E. Locatelli</a>, <a href="https://publications.waset.org/abstracts/search?q=I.%20Monaco"> I. Monaco</a>, <a href="https://publications.waset.org/abstracts/search?q=R.%20C.%20Martin"> R. C. Martin</a>, <a href="https://publications.waset.org/abstracts/search?q=Y.%20Li"> Y. Li</a>, <a href="https://publications.waset.org/abstracts/search?q=R.%20Pini"> R. Pini</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20Chiariello"> M. Chiariello</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20Comes%20Franchini"> M. Comes Franchini</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Despite the many advantages of application of nanomaterials in the field of nanomedicine, increasing concerns have been expressed on their potential adverse effects on human health. There is urgency for novel green strategies toward novel materials with enhanced biocompatibility using safe reagents. Photothermal ablation therapy, which exploits localized heat increase of a few degrees to kill cancer cells, has appeared recently as a non-invasive and highly efficient therapy against various cancer types; anyway new agents able to generate hyperthermia when irradiated are needed and must have precise biocompatibility in order to avoid damage to healthy tissues and prevent toxicity. Recently, there has been increasing interest in magnesium as a biomaterial: it is the fourth most abundant cation in the human body, and it is essential for human metabolism. However magnesium nanoparticles (Mg NPs) have had limited diffusion due to the high reduction potential of magnesium cations, which makes NPs synthesis challenging. Herein, we report the synthesis of Mg NPs and their surface functionalization for the obtainment of a stable and biocompatible nanomaterial suitable for photothermal ablation therapy against cancer. We synthesized the Mg crystals by reducing MgCl2 with metallic lithium and exploiting naphthalene as an electron carrier: the lithium–naphthalene complex acts as the real reducing agent. Firstly, the nanocrystal particles were coated with the ligand 12-ethoxy ester dodecanehydroxamic acid, and then entrapped into water-dispersible polymeric micelles (PMs) made of the FDA-approved PLGA-b-PEG-COOH copolymer using the oil-in-water emulsion technique. Lately, we developed a more straightforward methodology by introducing chitosan, a highly biocompatible natural product, at the beginning of the process, simultaneously using lithium–naphthalene complex, thus having a one-pot procedure for the formation and surface modification of MgNPs. The obtained MgNPs were purified and fully characterized, showing diameters in the range of 50-300 nm. Notably, when coated with chitosan the particles remained stable as dry powder for more than 10 months. We proved the possibility of generating a temperature rise of a few to several degrees once MgNPs were illuminated using a 810 nm diode laser operating in continuous wave mode: the temperature rise resulted significant (0-15 °C) and concentration dependent. We then investigated potential cytotoxicity of the MgNPs: we used HN13 epithelial cells, derived from a head and neck squamous cell carcinoma and the hepa1-6 cell line, derived from hepatocellular carcinoma and very low toxicity was observed for both nanosystems. Finally, in vivo photothermal therapy was performed on xenograft hepa1-6 tumor bearing mice: the animals were treated with MgNPs coated with chitosan and showed no sign of suffering after the injection. After 12 hours the tumor was exposed to near-infrared laser light. The results clearly showed an extensive damage to tumor tissue after only 2 minutes of laser irradiation at 3Wcm-1, while no damage was reported when the tumor was treated with the laser and saline alone in control group. Despite the lower photothermal efficiency of Mg with respect to Au NPs, we consider MgNPs a promising, safe and green candidate for future clinical translations. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=chitosan" title="chitosan">chitosan</a>, <a href="https://publications.waset.org/abstracts/search?q=magnesium%20nanoparticles" title=" magnesium nanoparticles"> magnesium nanoparticles</a>, <a href="https://publications.waset.org/abstracts/search?q=nanomedicine" title=" nanomedicine"> nanomedicine</a>, <a href="https://publications.waset.org/abstracts/search?q=photothermal%20therapy" title=" photothermal therapy"> photothermal therapy</a> </p> <a href="https://publications.waset.org/abstracts/48860/magnesium-nanoparticles-for-photothermal-therapy" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/48860.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">270</span> </span> </div> </div> </div> </main> <footer> <div id="infolinks" class="pt-3 pb-2"> <div class="container"> <div style="background-color:#f5f5f5;" class="p-3"> <div class="row"> <div class="col-md-2"> <ul class="list-unstyled"> About <li><a href="https://waset.org/page/support">About Us</a></li> <li><a href="https://waset.org/page/support#legal-information">Legal</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/WASET-16th-foundational-anniversary.pdf">WASET celebrates its 16th foundational anniversary</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Account <li><a href="https://waset.org/profile">My Account</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Explore <li><a href="https://waset.org/disciplines">Disciplines</a></li> <li><a href="https://waset.org/conferences">Conferences</a></li> <li><a href="https://waset.org/conference-programs">Conference Program</a></li> <li><a href="https://waset.org/committees">Committees</a></li> <li><a href="https://publications.waset.org">Publications</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Research <li><a href="https://publications.waset.org/abstracts">Abstracts</a></li> <li><a href="https://publications.waset.org">Periodicals</a></li> <li><a href="https://publications.waset.org/archive">Archive</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Open Science <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Science-Philosophy.pdf">Open Science Philosophy</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Science-Award.pdf">Open Science Award</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Society-Open-Science-and-Open-Innovation.pdf">Open Innovation</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Postdoctoral-Fellowship-Award.pdf">Postdoctoral Fellowship Award</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Scholarly-Research-Review.pdf">Scholarly Research Review</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Support <li><a href="https://waset.org/page/support">Support</a></li> <li><a href="https://waset.org/profile/messages/create">Contact Us</a></li> <li><a href="https://waset.org/profile/messages/create">Report Abuse</a></li> </ul> </div> </div> </div> </div> </div> <div class="container text-center"> <hr style="margin-top:0;margin-bottom:.3rem;"> <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank" class="text-muted small">Creative Commons Attribution 4.0 International License</a> <div id="copy" class="mt-2">© 2024 World Academy of Science, Engineering and Technology</div> </div> </footer> <a href="javascript:" id="return-to-top"><i class="fas fa-arrow-up"></i></a> <div class="modal" id="modal-template"> <div class="modal-dialog"> <div class="modal-content"> <div class="row m-0 mt-1"> <div class="col-md-12"> <button type="button" class="close" data-dismiss="modal" aria-label="Close"><span aria-hidden="true">×</span></button> </div> </div> <div class="modal-body"></div> </div> </div> </div> <script src="https://cdn.waset.org/static/plugins/jquery-3.3.1.min.js"></script> <script src="https://cdn.waset.org/static/plugins/bootstrap-4.2.1/js/bootstrap.bundle.min.js"></script> <script src="https://cdn.waset.org/static/js/site.js?v=150220211556"></script> <script> jQuery(document).ready(function() { /*jQuery.get("https://publications.waset.org/xhr/user-menu", function (response) { jQuery('#mainNavMenu').append(response); });*/ jQuery.get({ url: "https://publications.waset.org/xhr/user-menu", cache: false }).then(function(response){ jQuery('#mainNavMenu').append(response); }); }); </script> </body> </html>